burning rock biotech ltd. - BNR

BNR

Close Chg Chg %
31.06 8.69 27.98%

Open Market

39.75

+8.69 (27.98%)

Volume: 96.52K

Last Updated:

Jan 22, 2026, 2:43 PM EDT

Company Overview: burning rock biotech ltd. - BNR

BNR Key Data

Open

$29.96

Day Range

29.96 - 39.97

52 Week Range

2.18 - 34.44

Market Cap

$280.60M

Shares Outstanding

9.03M

Public Float

9.01M

Beta

1.27

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.61

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

32.26K

 

BNR Performance

1 Week
 
-2.97%
 
1 Month
 
46.68%
 
3 Months
 
137.92%
 
1 Year
 
324.51%
 
5 Years
 
-91.52%
 

BNR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About burning rock biotech ltd. - BNR

Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.

BNR At a Glance

Burning Rock Biotech Ltd.
No 5 Xingdao Ring Road North
Guangzhou, Guangdong 510005
Phone 86-20-34037871 Revenue 71.67M
Industry Medical/Nursing Services Net Income -48,163,788.61
Sector Health Services Employees 674
Fiscal Year-end 12 / 2025
View SEC Filings

BNR Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.969
Price to Book Ratio 0.913
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -0.136
Enterprise Value to Sales 0.071
Total Debt to Enterprise Value 1.402

BNR Efficiency

Revenue/Employee 106,340.689
Income Per Employee -71,459.627
Receivables Turnover 3.016
Total Asset Turnover 0.535

BNR Liquidity

Current Ratio 2.916
Quick Ratio 2.681
Cash Ratio 1.961

BNR Profitability

Gross Margin 70.257
Operating Margin -62.508
Pretax Margin -66.058
Net Margin -67.199
Return on Assets -35.953
Return on Equity -51.26
Return on Total Capital -55.526
Return on Invested Capital -50.107

BNR Capital Structure

Total Debt to Total Equity 9.008
Total Debt to Total Capital 8.264
Total Debt to Total Assets 5.91
Long-Term Debt to Equity 4.778
Long-Term Debt to Total Capital 4.383
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Burning Rock Biotech Ltd. - BNR

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
78.75M 83.64M 75.86M 71.67M
Sales Growth
+26.43% +6.22% -9.31% -5.51%
Cost of Goods Sold (COGS) incl D&A
22.28M 27.21M 24.59M 21.32M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.41M 18.43M 18.83M 7.25M
Depreciation
6.92M 17.93M 18.55M 7.14M
Amortization of Intangibles
490.28K 497.35K 274.95K 112.97K
COGS Growth
+32.61% +22.09% -9.62% -13.30%
Gross Income
56.46M 56.44M 51.27M 50.36M
Gross Income Growth
+24.14% -0.04% -9.16% -1.78%
Gross Profit Margin
+71.70% +67.47% +67.59% +70.26%
2021 2022 2023 2024 5-year trend
SG&A Expense
180.05M 202.04M 145.74M 95.16M
Research & Development
57.04M 62.65M 48.98M 32.28M
Other SG&A
123.01M 139.38M 96.76M 62.88M
SGA Growth
+71.10% +12.21% -27.87% -34.71%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 4.88M
-
EBIT after Unusual Expense
(123.59M) (145.60M) (94.47M) (49.68M)
Non Operating Income/Expense
434.46K 1.66M 2.54M 2.34M
Non-Operating Interest Income
536.02K 1.40M 2.53M 1.70M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 238.16K
-
Interest Expense Growth
- - - +146.46%
-
Gross Interest Expense
- - - 238.16K
-
Interest Capitalized
- - - -
-
Pretax Income
(123.39M) (143.94M) (91.93M) (47.35M)
Pretax Income Growth
-109.14% -16.65% +36.14% +48.50%
Pretax Margin
-156.70% -172.08% -121.19% -66.06%
Income Tax
139.39K 294.79K 337.05K 817.72K
Income Tax - Current - Domestic
139.39K 294.79K 337.05K 817.72K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(123.53M) (144.23M) (92.26M) (48.16M)
Minority Interest Expense
- - - -
-
Net Income
(123.53M) (144.23M) (92.26M) (48.16M)
Net Income Growth
-109.37% -16.76% +36.03% +47.80%
Net Margin Growth
-156.87% -172.44% -121.63% -67.20%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(123.53M) (144.23M) (92.26M) (48.16M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(123.53M) (144.23M) (92.26M) (48.16M)
EPS (Basic)
-11.8543 -13.8808 -9.0105 -4.679
EPS (Basic) Growth
-19.00% -17.10% +35.09% +48.07%
Basic Shares Outstanding
10.42M 10.39M 10.24M 10.29M
EPS (Diluted)
-11.8543 -13.8808 -9.0105 -4.679
EPS (Diluted) Growth
-19.00% -17.10% +35.09% +48.07%
Diluted Shares Outstanding
10.42M 10.39M 10.24M 10.29M
EBITDA
(116.18M) (127.17M) (75.64M) (37.55M)
EBITDA Growth
-111.53% -9.46% +40.52% +50.36%
EBITDA Margin
-147.54% -152.03% -99.72% -52.39%

Burning Rock Biotech Ltd. in the News